Estee Lauder, Moderna, Merck And Other Big Stocks Moving Higher On Wednesday

Shares of precious metal-related companies are trading lower as climbing yields and a stronger dollar raise rate-hike expectations. President Trump's rejection of Iran's plan to reopen the Strait of Hormuz and a possible diesel export ban are boosting oil prices and contributing to mounting inflationary concerns as regional conflict continues.

Shares of precious metals-related companies are trading lower as gold and silver decline amid a stronger dollar and rising yields. Recent comments from the Fed's Barkin on inflation and future rate hikes prompt expectations of tighter monetary policy, which would create headwinds as investors rotate into fixed income.

Algoma Steel Group Inc. Provides Guidance for the Third Quarter 2026

Algoma Steel reported Q3 2026 guidance with expected steel shipments of approximately 145,000 tons and Adjusted EBITDA between negative $10-20 million. The company successfully restored full power at Lake Superior Power plant after a turbine replacement and expects first heat from EAF Unit Two in the coming days. Despite near-term headwinds from the power outage and lower shipment volumes, management expressed optimism about improved steel prices and the company's transformation progress.

Algoma Steel Group Says Total Steel Shipments For The Quarter Are Expected To Be ~145,000 Tons And Adjusted EBITDA Is Expected To Be In The Range Of Negative CAD$10M To Negative CAD$20M

Algoma Steel Group Inc. (NASDAQ:ASTL, TSX:ASTL) ("Algoma" or "the Company"), a leading Canadian producer of steel plate and hot rolled sheet products, today provided guidance for its quarter ended

President Trump Says If We Don't Make Steel Ourselves, We Can't Defend Ourselves

https://www.youtube.com/watch?v=TmNee1tFImc

Head and Neck Squamous Cell Carcinoma (HNSCC) - Market Insights, Epidemiology, and Market Forecast - 2036 | Set to Reach $2.56 Billion as HPV-Targeted Vaccines Reshape Care

The HNSCC market is projected to grow from $850 million in 2025 to $2.56 billion by 2036 (10.5% CAGR), driven by HPV-targeted vaccines, checkpoint inhibitors, and biomarker-led patient selection. The US will remain the largest market at $2.082 billion. Key therapies include KEYTRUDA and OPDIVO, with emerging candidates like petosemtamab and amivantamab showing promise in clinical development.